Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of First Line Bortezomib, Rituximab, Ibrutinib (B-RI) for Patients With Treatment Naive Waldenström's Macroglobulinemia

NCT03620903 is registered in ClinicalTrials.gov with Christian Buske as lead sponsor.

NCT NCT03620903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03620903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of First Line Bortezomib, Rituximab, Ibrutinib (B-RI) for Patients With Treatment Naive Waldenström's Macroglobulinemia
Lead sponsor
Christian Buske
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 11, 2019
Completion date
February 28, 2027
Enrollment
53 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom macroglobulinemia